Skip to main content
main-content

2018 ACR/ARHP Annual Meeting coverage

Featured research: Improving the immune response to influenza vaccination in RA patients

25-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

Improving immune response against influenza in patients with RA

Inés Colmegna talks to us about her study showing the impact of a high-dose influenza vaccine on the immune response of patients with rheumatoid arthritis (11:17).

21-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

High-dose influenza vaccine enhances immune response in RA patients

Administration of a high-dose influenza vaccine results in an improved humoral immune response when given to patients with rheumatoid arthritis, suggest findings from a randomized controlled trial.

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

Expert commentary: Influzena vaccination in RA patients

Infectious disease specialist Kevin Winthrop comments on the study by Inés Colmegna and colleagues looking at the effects of a high-dose influenza vaccine on immune response in patients with rheumatoid arthritis (6:27).

Featured research: Predicting RA-ILD risk

22-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

MUC5B promoter variant tied to RA-ILD risk

Individuals who carry the MUC5B promoter variant rs35705950 have an elevated risk for rheumatoid arthritis-associated interstitial lung disease, researchers report.

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

MUC5B promoter variant identified as a risk factor for RA-ILD

Philippe Dieudé discusses the results of a study demonstrating that the MUC5B promoter variant rs35705950 is linked to rheumatoid arthritis-associated interstitial disease susceptibility (3:01).

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

Interstitial lung disease risk linked to rheumatoid arthritis disease severity

Moderate-to-high rheumatoid arthritis disease activity is associated with a twofold increased risk for associated interstitial lung disease, compared with remission or low disease activity, study findings show.

Research news

01-11-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

Tocilizumab-treated RA patients with LDA ‘should be considered’ for glucocorticoid tapering

Findings from a randomized controlled trial suggest that glucocorticoid tapering is a feasible strategy for rheumatoid arthritis patients who achieve low disease activity or remission during treatment with tocilizumab and long-term glucocorticoids.

31-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | News

Post-hoc analysis supports further investigation of ustekinumab in PsA-associated spondylitis

Treatment with ustekinumab may be beneficial for some patients with psoriatic arthritis and spondylitis, suggests a post-hoc subgroup analysis of the PSUMMIT 1 and 2 trials.

29-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

Peficitinib may be a promising treatment option for RA

Findings from two phase III trials presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA, demonstrate that treatment with the JAK inhibitor peficitinib may be beneficial for patients with rheumatoid arthritis.

Video interviews

27-10-2018 | Denosumab | ACR/ARHP 2018 | Video

Support for denosumab as a treatment option for osteoporosis in patients treated with glucocorticoids

Kenneth Saag discusses his findings of a superior bone mineral density benefit at 2 years with denosumab versus risedronate in patients with glucocorticoid-related osteoporosis (4:45).

25-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

Improving immune response against influenza in patients with RA

Inés Colmegna talks to us about her study showing the impact of a high-dose influenza vaccine on the immune response of patients with rheumatoid arthritis (11:17).

24-10-2018 | Cardiovascular disease | ACR/ARHP 2018 | Video

Looking to collaborative models of care to improve primary prevention of CVD in patients with inflammatory arthritis

Lihi Eder describes a new model of care based on collaboration between cardiologists and rheumatologists to better manage cardiovascular risk factors in patients with inflammatory arthritis (5:56).

24-10-2018 | Pediatric | ACR/ARHP 2018 | Video

Expert highlights: Sangeeta Sule

Editorial board member Sangeeta Sule discusses her highlights from the pediatric rheumatology sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA (2:14).

24-10-2018 | Systemic lupus erythematosus | ACR/ARHP 2018 | Video

Ustekinumab shows potential for the treatment of SLE

Ronald van Vollenhoven discusses phase II trial results demonstrating that the interkeukin-12/23 inhibitor ustekinumab may be a promising treatment option for systemic lupus erythematosus (5:36).

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

Expert commentary: Influzena vaccination in RA patients

Infectious disease specialist Kevin Winthrop comments on the study by Inés Colmegna and colleagues looking at the effects of a high-dose influenza vaccine on immune response in patients with rheumatoid arthritis (6:27).

23-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | Video

MUC5B promoter variant identified as a risk factor for RA-ILD

Philippe Dieudé discusses the results of a study demonstrating that the MUC5B promoter variant rs35705950 is linked to rheumatoid arthritis-associated interstitial disease susceptibility (3:01).

22-10-2018 | Giant cell arteritis | ACR/ARHP 2018 | Video

Axillary artery ultrasound proposed as first-line imaging test for large vessel giant cell arteritis

Berit Dalsgaard Nielsen discusses Aarhus University study findings showing the potential for ultrasound as a first-line imaging test for diagnosing large vessel inflammation in patients with suspected giant cell arteritis (4:57).

image credits